Get the Stockscreener App
10.39
1.86%
0.19
Moonlake Immunotherapeutics stock is traded at $10.39, with a volume of 1.44M.
It is up +1.86% in the last 24 hours and up +23.25% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$10.20
Open:
$10.05
24h Volume:
1.44M
Relative Volume:
0.34
Market Cap:
$659.78M
Revenue:
-
Net Income/Loss:
$-145.21M
P/E Ratio:
-4.5174
EPS:
-2.3
Net Cash Flow:
$-140.12M
1W Performance:
+5.80%
1M Performance:
+23.25%
6M Performance:
-75.45%
1Y Performance:
-77.61%
1-Day Range:
$9.96
$10.60
1-Week Range:
$9.37
$10.60
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
10.39 | 647.71M | 0 | -145.21M | -140.12M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.66 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
629.42 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.43 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.29 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.45 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
ROSEN, NATIONAL TRIAL COUNSEL, Encourages MoonLake - GlobeNewswire
ROSEN, NATIONAL TRIAL COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure ... - Bluefield Daily Telegraph
MLTX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
Check out these key findings about MoonLake Immunotherapeutics (MLTX) - setenews.com
MoonLake Immunotherapeutics (NASDAQ:MLTX) Rating Increased to Buy at HC Wainwright - MarketBeat
Levi & Korsinsky Notifies MoonLake Immunotherapeutics - GlobeNewswire
Deadline Alert: MoonLake Immunotherapeutics (MLTX) - GlobeNewswire
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.
MLTX Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MLTX To Contact Him Directly To Discuss Their Options - MarketScreener
MLTX INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In MLTX To Contact Him Directly To Discuss Their Options - PR Newswire
Securities Class Action Lawsuit Filed Against MoonLake Immunotherapeutics (MLTX)Levi & Korsinsky Represents Shareholders - The Globe and Mail
Lost Money on MoonLake Immunotherapeutics(MLTX)? Join Class Acti - GuruFocus
MLTX CLASS ACTION NOTICE: Berger Montague Encourages MoonLake Immunotherapeutics (NASDAQ - MarketScreener
Lost Money on MoonLake Immunotherapeutics(MLTX)? Join Class Action Suit Seeking RecoveryContact The Gross Law Firm - MarketScreener
MLTX INVESTOR CLASS ACTION: MoonLake Immunotherapeutics has - GlobeNewswire
H.C. Wainwright upgrades Moonlake stock rating to Buy with $30 price target - Investing.com
HC Wainwright & Co. Upgrades MoonLake Immunotherapeutics (MLTX) - Nasdaq
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds ... - Bluefield Daily Telegraph
MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER - GlobeNewswire
2025-11-02 | Join Class Action to Recover Losses from MoonLake Immunotherapeutics (MLTX)Contact Levi & Korsinsky Before December 15, 2025 | NDAQ:MLTX | Press Release - Stockhouse
2025-11-02 | MLTX ALERT: Securities Fraud Class Action Launched Against MoonLake ImmunotherapeuticsDecember 15, 2025 Deadline | NDAQ:MLTX | Press Release - Stockhouse
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages MoonLake Immunotherapeutics Investors to ... - Bluefield Daily Telegraph
Quantitative breakdown of MoonLake Immunotherapeutics recent moveTrade Analysis Summary & Verified Entry Point Detection - newser.com
Can MoonLake Immunotherapeutics stock deliver sustainable ROEJuly 2025 Gainers & Verified Technical Signals - newser.com
MoonLake Immunotherapeutics Class Action: MLTX Stockholders Shou - GuruFocus
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading 6.7% HigherShould You Buy? - MarketBeat
MoonLake Immunotherapeutics Class Action: MLTX Stockholders Should Contact Robbins LLP for Information About the Class Action Against - Morningstar
Levi & Korsinsky Notifies MoonLake Immunotherapeutics (MLTX) InvestorsLead Plaintiff Deadline on December 15, 2025 - Newsfile
MoonLake Immunotherapeutics Securities Fraud Class Action - GlobeNewswire
MLTX Investors Have Opportunity to Lead MoonLake - GlobeNewswire
MoonLake Immunotherapeutics (MLTX) Faces Securities Class - GlobeNewswire
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics - Newsfile
Visualizing MoonLake Immunotherapeutics stock with heatmapsJuly 2025 Update & Short-Term Trading Opportunity Alerts - newser.com
Can MoonLake Immunotherapeutics stock beat analyst upgradesJuly 2025 Pullbacks & Daily Stock Momentum Reports - newser.com
How MoonLake Immunotherapeutics stock trades during market volatilityQuarterly Trade Summary & Verified Entry Point Signals - newser.com
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit - Business Wire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Moonlake Immunotherapeutics, Inc. Investors - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in MoonLake Immunotherapeutics of Class Action Lawsuit and Upcoming DeadlinesMLTX - FinancialContent
MLTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - PR Newswire
The Gross Law Firm Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming DeadlineMLTX - MarketScreener
MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday - MarketBeat
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) - openPR.com
Deadline Approaching: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - MarketScreener
Shareholders SueWallSt in New Class Action Against MoonLake ImmunotherapeuticsAct Now - Nasdaq
MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate -- Hagens Berman - GlobeNewswire
MoonLake Immunotherapeutics downgraded to Sell from Neutral at Citi - TipRanks
MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
MLTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MoonLake Immunotherapeutics Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Moonlake Immunotherapeutics Stock (MLTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chen Bihua | Former 10% Owner |
Sep 29 '25 |
Sale |
7.21 |
6,494,151 |
46,827,628 |
2,000,000 |
| Chen Bihua | Former 10% Owner |
Sep 30 '25 |
Sale |
6.96 |
5,827 |
40,556 |
1,994,173 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Option Exercise |
0.00 |
23,500 |
0 |
23,500 |
| Moukheibir Catherine | Director |
Jul 03 '25 |
Sale |
48.79 |
23,500 |
1,146,565 |
0 |
1.24%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):